Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine‐Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway
Drug Testing and Analysis · 2025-11 · 17 (11) · 2276-2282
DOI: 10.1002/dta.3940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, online erschienen am 07.08.2025. Verfasst von Anders Helander und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Methamphetamine, Substance Abuse Detection, Amphetamine, Central Nervous System Stimulants. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Methamphetamine is relatively uncommon on the European drug market, but Swedish drug test laboratories repeatedly detect low methamphetamine concentrations in urine samples containing high amphetamine levels, warranting clinical evaluation for suspected polydrug use. Of 12,062 routine samples screened positive for amphetamines, 86% were confirmed positive (≥ 200 μg/L) for amphetamine, 2.1% for methamphetamine, and 4.0% for 3,4‐methylenedioxymethamphetamine (ecstasy) by liquid chromatography–tandem mass spectrometry. Of the 259 methamphetamine‐positive samples, 98% contained amphetamine concentrations above the reporting limit, consistent with the metabolic conversion of methamphetamine to amphetamine in the body. However, in most (69%) of these samples, the methamphetamine concentration was only < 2% of the amphetamine level, suggesting methamphetamine was not the primary drug taken. Chiral analysis of selected samples showed that after use of illicit street amphetamine with a racemic content of the l ‐ and d ‐enantiomers, a similar l/d proportion was observed for methamphetamine. Similarly, in samples from patients receiving d ‐amphetamine‐based ADHD medication, low d ‐methamphetamine levels were detected, even though the pharmaceutical products contained no methamphetamine. This observation, together with the parallel l/d ‐enantiomer distributions, supports amphetamine N ‐methylation as a trace, albeit quantitatively insignificant, metabolic pathway in humans. From both a clinical and forensic perspective, a low urinary methamphetamine concentration of less than a few percent of the amphetamine level therefore does not warrant further clinical evaluation for suspected polydrug use. The present findings further demonstrate that chiral analysis of both amphetamine and methamphetamine is an effective approach for distinguishing between illicit and therapeutic sources in positive screening drug tests for the amphetamines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Clinical Chemistry, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Anders Helander
Zitieren
APA
Helander, A., Andersson, A., & Villén, T. (2025). Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine‐Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway. Drug Testing and Analysis, 17(11), 2276-2282. https://doi.org/10.1002/dta.3940
Vancouver
Helander A, Andersson A, Villén T. Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine‐Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway. Drug Testing and Analysis. 2025;17(11):2276-2282. doi:10.1002/dta.3940
BibTeX
@article{Helander2025,
author = {Helander, Anders and Andersson, Annika and Villén, Tomas},
title = {Origin and Interpretation of Low Methamphetamine Levels Found in Amphetamine‐Positive Urine Samples: Support for Methylation of Amphetamine as a Minor Metabolic Pathway},
journal = {Drug Testing and Analysis},
year = {2025},
volume = {17},
number = {11},
pages = {2276--2282},
doi = {10.1002/dta.3940}
}
EUVIMED